This systematic review identifies and critically evaluates the mechanistic and clinical evidence of new promising therapeutic targets in hidradenitis suppurativa (HS). Evidence for these targets is largely based on observational data with limited ex vivo and translational data from clinical trials. A number of placebo-controlled studies have been completed or are underway utilizing IL-1, IL-23, IL-17, complement, and Jak inhibition, although there is concern regarding elevated placebo response rates and the questionable validity of clinical scores in some participant subsets. Knowledge gaps are identified suggesting a direction for future mechanistic studies in HS, including more comprehensive inflammatory endotype profiling of disease.

A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa : A Critical Evaluation of Mechanistic and Clinical Relevance / J.W. Frew, A.V. Marzano, K. Wolk, O. Join-Lambert, A. Alavi, M.A. Lowes, V. Piguet. - In: JOURNAL OF INVESTIGATIVE DERMATOLOGY. - ISSN 0022-202X. - 141:2(2021), pp. 316-324. [10.1016/j.jid.2020.06.019]

A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa : A Critical Evaluation of Mechanistic and Clinical Relevance

A.V. Marzano;
2021

Abstract

This systematic review identifies and critically evaluates the mechanistic and clinical evidence of new promising therapeutic targets in hidradenitis suppurativa (HS). Evidence for these targets is largely based on observational data with limited ex vivo and translational data from clinical trials. A number of placebo-controlled studies have been completed or are underway utilizing IL-1, IL-23, IL-17, complement, and Jak inhibition, although there is concern regarding elevated placebo response rates and the questionable validity of clinical scores in some participant subsets. Knowledge gaps are identified suggesting a direction for future mechanistic studies in HS, including more comprehensive inflammatory endotype profiling of disease.
Growth-factor-beta; elevated levels; TNF-alpha; moderate; placebo; pathway; disease; skin; acne; inflammation
Settore MED/35 - Malattie Cutanee e Veneree
2021
9-set-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0022202X20318261-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.02 MB
Formato Adobe PDF
1.02 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/782277
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 41
social impact